Pub Date : 2024-08-15DOI: 10.1164/rccm.202306-0979OC
Avraham Unterman, Amy Y Zhao, Nir Neumark, Jonas C Schupp, Farida Ahangari, Carlos Cosme, Prapti Sharma, Jasper Flint, Yan Stein, Changwan Ryu, Genta Ishikawa, Tomokazu S Sumida, Jose L Gomez, Jose D Herazo-Maya, Charles S Dela Cruz, Erica L Herzog, Naftali Kaminski
Rationale: Changes in peripheral blood cell populations have been observed, but not detailed, at single-cell resolution in idiopathic pulmonary fibrosis (IPF). Objectives: We sought to provide an atlas of the changes in the peripheral immune system in stable and progressive IPF. Methods: Peripheral blood mononuclear cells (PBMCs) from patients with IPF and control subjects were profiled using 10× chromium 5' single-cell RNA sequencing. Flow cytometry was used for validation. Protein concentrations of regulatory T cells (Tregs) and monocyte chemoattractants were measured in plasma and lung homogenates from patients with IPF and control subjects. Measurements and Main Results: Thirty-eight PBMC samples from 25 patients with IPF and 13 matched control subjects yielded 149,564 cells that segregated into 23 subpopulations. Classical monocytes were increased in patients with progressive and stable IPF compared with control subjects (32.1%, 25.2%, and 17.9%, respectively; P < 0.05). Total lymphocytes were decreased in patients with IPF versus control subjects and in progressive versus stable IPF (52.6% vs. 62.6%, P = 0.035). Tregs were increased in progressive versus stable IPF (1.8% vs. 1.1% of all PBMCs, P = 0.007), although not different than controls, and may be associated with decreased survival (P = 0.009 in Kaplan-Meier analysis; and P = 0.069 after adjusting for age, sex, and baseline FVC). Flow cytometry analysis confirmed this finding in an independent cohort of patients with IPF. The fraction of Tregs out of all T cells was also increased in two cohorts of lung single-cell RNA sequencing. CCL22 and CCL18, ligands for CCR4 and CCR8 Treg chemotaxis receptors, were increased in IPF. Conclusions: The single-cell atlas of the peripheral immune system in IPF reveals an outcome-predictive increase in classical monocytes and Tregs, as well as evidence for a lung-blood immune recruitment axis involving CCL7 (for classical monocytes) and CCL18/CCL22 (for Tregs).
{"title":"Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis.","authors":"Avraham Unterman, Amy Y Zhao, Nir Neumark, Jonas C Schupp, Farida Ahangari, Carlos Cosme, Prapti Sharma, Jasper Flint, Yan Stein, Changwan Ryu, Genta Ishikawa, Tomokazu S Sumida, Jose L Gomez, Jose D Herazo-Maya, Charles S Dela Cruz, Erica L Herzog, Naftali Kaminski","doi":"10.1164/rccm.202306-0979OC","DOIUrl":"10.1164/rccm.202306-0979OC","url":null,"abstract":"<p><p><b>Rationale:</b> Changes in peripheral blood cell populations have been observed, but not detailed, at single-cell resolution in idiopathic pulmonary fibrosis (IPF). <b>Objectives:</b> We sought to provide an atlas of the changes in the peripheral immune system in stable and progressive IPF. <b>Methods:</b> Peripheral blood mononuclear cells (PBMCs) from patients with IPF and control subjects were profiled using 10× chromium 5' single-cell RNA sequencing. Flow cytometry was used for validation. Protein concentrations of regulatory T cells (Tregs) and monocyte chemoattractants were measured in plasma and lung homogenates from patients with IPF and control subjects. <b>Measurements and Main Results:</b> Thirty-eight PBMC samples from 25 patients with IPF and 13 matched control subjects yielded 149,564 cells that segregated into 23 subpopulations. Classical monocytes were increased in patients with progressive and stable IPF compared with control subjects (32.1%, 25.2%, and 17.9%, respectively; <i>P</i> < 0.05). Total lymphocytes were decreased in patients with IPF versus control subjects and in progressive versus stable IPF (52.6% vs. 62.6%, <i>P</i> = 0.035). Tregs were increased in progressive versus stable IPF (1.8% vs. 1.1% of all PBMCs, <i>P</i> = 0.007), although not different than controls, and may be associated with decreased survival (<i>P</i> = 0.009 in Kaplan-Meier analysis; and <i>P</i> = 0.069 after adjusting for age, sex, and baseline FVC). Flow cytometry analysis confirmed this finding in an independent cohort of patients with IPF. The fraction of Tregs out of all T cells was also increased in two cohorts of lung single-cell RNA sequencing. CCL22 and CCL18, ligands for CCR4 and CCR8 Treg chemotaxis receptors, were increased in IPF. <b>Conclusions:</b> The single-cell atlas of the peripheral immune system in IPF reveals an outcome-predictive increase in classical monocytes and Tregs, as well as evidence for a lung-blood immune recruitment axis involving CCL7 (for classical monocytes) and CCL18/CCL22 (for Tregs).</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202403-0636OC
Lisa Lancaster, Vincent Cottin, Murali Ramaswamy, Wim A Wuyts, R Gisli Jenkins, Mary Beth Scholand, Michael Kreuter, Claudia Valenzuela, Christopher J Ryerson, Jonathan Goldin, Grace Hyun J Kim, Marzena Jurek, Martin Decaris, Annie Clark, Scott Turner, Chris N Barnes, Hardean E Achneck, Gregory P Cosgrove, Éric A Lefebvre, Kevin R Flaherty
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).
{"title":"Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.","authors":"Lisa Lancaster, Vincent Cottin, Murali Ramaswamy, Wim A Wuyts, R Gisli Jenkins, Mary Beth Scholand, Michael Kreuter, Claudia Valenzuela, Christopher J Ryerson, Jonathan Goldin, Grace Hyun J Kim, Marzena Jurek, Martin Decaris, Annie Clark, Scott Turner, Chris N Barnes, Hardean E Achneck, Gregory P Cosgrove, Éric A Lefebvre, Kevin R Flaherty","doi":"10.1164/rccm.202403-0636OC","DOIUrl":"10.1164/rccm.202403-0636OC","url":null,"abstract":"<p><p><b>Rationale:</b> Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. <b>Objectives:</b> Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. <b>Methods:</b> This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. <b>Measurements and Main Results:</b> Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. <b>Conclusions:</b> Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202312-2357LE
Julia K Munchel, Abhinav K Misra, Scott A Collins, Ryan DiGregorio, Amy Palmisciano, Pedram Heidari, Richard B Noto, Sydney B Montesi, Peter Caravan, Barry S Shea
{"title":"Fibrin-Positron Emission Tomography Imaging Reveals Ongoing Lung Injury in Idiopathic Pulmonary Fibrosis.","authors":"Julia K Munchel, Abhinav K Misra, Scott A Collins, Ryan DiGregorio, Amy Palmisciano, Pedram Heidari, Richard B Noto, Sydney B Montesi, Peter Caravan, Barry S Shea","doi":"10.1164/rccm.202312-2357LE","DOIUrl":"10.1164/rccm.202312-2357LE","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202404-0767RL
Bo-Guen Kim, Kyungdo Han, Jin-Hyung Jung, Dong Won Park, Sang-Heon Kim, Jang Won Sohn, Ho Joo Yoon, Hyun Lee
{"title":"Risk of Suicide in Individuals with Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study.","authors":"Bo-Guen Kim, Kyungdo Han, Jin-Hyung Jung, Dong Won Park, Sang-Heon Kim, Jang Won Sohn, Ho Joo Yoon, Hyun Lee","doi":"10.1164/rccm.202404-0767RL","DOIUrl":"10.1164/rccm.202404-0767RL","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202406-1277ED
Shaikh M Atif, Wonder P Drake
{"title":"Renin-Angiotensin-Aldosterone System: A Potential Source of Biomarkers and Therapeutic Targets for Sarcoidosis.","authors":"Shaikh M Atif, Wonder P Drake","doi":"10.1164/rccm.202406-1277ED","DOIUrl":"10.1164/rccm.202406-1277ED","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202312-2224LE
William Whalen, Kristin Berger, John S Kim, Will Simmons, Shwu-Fan Ma, Robert J Kaner, Fernando J Martinez, Kevin J Anstrom, Helen Parfrey, Toby M Maher, Matthew Hammond, Allan B Clark, David Thickett, R Gisli Jenkins, Andrew M Wilson, Imre Noth
{"title":"<i>TOLLIP</i> SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.","authors":"William Whalen, Kristin Berger, John S Kim, Will Simmons, Shwu-Fan Ma, Robert J Kaner, Fernando J Martinez, Kevin J Anstrom, Helen Parfrey, Toby M Maher, Matthew Hammond, Allan B Clark, David Thickett, R Gisli Jenkins, Andrew M Wilson, Imre Noth","doi":"10.1164/rccm.202312-2224LE","DOIUrl":"10.1164/rccm.202312-2224LE","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202406-1164ED
Alexandra L McCubbrey, William J Janssen
{"title":"Using a Single-Cell Atlas of Peripheral Blood Mononuclear Cells to Understand Disease Trajectories in Idiopathic Pulmonary Fibrosis.","authors":"Alexandra L McCubbrey, William J Janssen","doi":"10.1164/rccm.202406-1164ED","DOIUrl":"10.1164/rccm.202406-1164ED","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202405-1089ED
Kristin Berger, Anna J Podolanczuk
{"title":"Bystander No More: Small Airway Involvement in Idiopathic Pulmonary Fibrosis.","authors":"Kristin Berger, Anna J Podolanczuk","doi":"10.1164/rccm.202405-1089ED","DOIUrl":"10.1164/rccm.202405-1089ED","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202310-1907OC
Waldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, Francesco Bonella, Rodney J Folz, J Douglass Rolf, Nesrin Mogulkoc, Lisa H Lancaster, R Gisli Jenkins, David A Lynch, Paul W Noble, Toby M Maher, Vincent Cottin, Stefanie Senger, Gerald S Horan, Steven Greenberg, Zoran Popmihajlov
Rationale: Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options. Objectives: We sought to assess the efficacy and safety of CC-90001, an oral inhibitor of c-Jun N-terminal kinase 1, in patients with idiopathic pulmonary fibrosis. Methods: In a Phase 2, randomized (1:1:1), double-blind, placebo-controlled study (ClinicalTrials.gov ID: NCT03142191), patients received CC-90001 (200 or 400 mg) or placebo once daily for 24 weeks. Background antifibrotic treatment (pirfenidone) was allowed. The primary endpoint was change in the percentage of predicted FVC (ppFVC) from baseline to Week 24; secondary endpoints included safety. Measurements and Main Results: In total, 112 patients received at least one dose of study drug. The study was terminated early because of a strategic decision made by the sponsor. Ninety-one patients (81%) completed the study. The least-squares mean changes from baseline in ppFVC at Week 24 were -3.1% (placebo), -2.1% (200 mg), and -1.0% (400 mg); the differences compared with placebo were 1.1% (200 mg; 95% confidence interval: -2.1, 4.3; P = 0.50) and 2.2% (400 mg; 95% confidence interval: -1.1, 5.4; P = 0.19). Adverse event frequency was similar in patients in the combined CC-90001 arms versus placebo. The most common adverse events were nausea, diarrhea, and vomiting, which were more frequent in patients in CC-90001 arms versus placebo. Fewer patients in the CC-90001 arms than in the placebo arm experienced cough and dyspnea. Conclusions: Treatment with CC-90001 over 24 weeks led to numerical improvements in ppFVC in patients with idiopathic pulmonary fibrosis compared with placebo. CC-90001 was generally well tolerated, which was consistent with previous studies. Clinical trial registered with www.clinicaltrials.gov (NCT03142191).
{"title":"Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis.","authors":"Waldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, Francesco Bonella, Rodney J Folz, J Douglass Rolf, Nesrin Mogulkoc, Lisa H Lancaster, R Gisli Jenkins, David A Lynch, Paul W Noble, Toby M Maher, Vincent Cottin, Stefanie Senger, Gerald S Horan, Steven Greenberg, Zoran Popmihajlov","doi":"10.1164/rccm.202310-1907OC","DOIUrl":"10.1164/rccm.202310-1907OC","url":null,"abstract":"<p><p><b>Rationale:</b> Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options. <b>Objectives:</b> We sought to assess the efficacy and safety of CC-90001, an oral inhibitor of c-Jun N-terminal kinase 1, in patients with idiopathic pulmonary fibrosis. <b>Methods:</b> In a Phase 2, randomized (1:1:1), double-blind, placebo-controlled study (ClinicalTrials.gov ID: NCT03142191), patients received CC-90001 (200 or 400 mg) or placebo once daily for 24 weeks. Background antifibrotic treatment (pirfenidone) was allowed. The primary endpoint was change in the percentage of predicted FVC (ppFVC) from baseline to Week 24; secondary endpoints included safety. <b>Measurements and Main Results:</b> In total, 112 patients received at least one dose of study drug. The study was terminated early because of a strategic decision made by the sponsor. Ninety-one patients (81%) completed the study. The least-squares mean changes from baseline in ppFVC at Week 24 were -3.1% (placebo), -2.1% (200 mg), and -1.0% (400 mg); the differences compared with placebo were 1.1% (200 mg; 95% confidence interval: -2.1, 4.3; <i>P</i> = 0.50) and 2.2% (400 mg; 95% confidence interval: -1.1, 5.4; <i>P</i> = 0.19). Adverse event frequency was similar in patients in the combined CC-90001 arms versus placebo. The most common adverse events were nausea, diarrhea, and vomiting, which were more frequent in patients in CC-90001 arms versus placebo. Fewer patients in the CC-90001 arms than in the placebo arm experienced cough and dyspnea. <b>Conclusions:</b> Treatment with CC-90001 over 24 weeks led to numerical improvements in ppFVC in patients with idiopathic pulmonary fibrosis compared with placebo. CC-90001 was generally well tolerated, which was consistent with previous studies. Clinical trial registered with www.clinicaltrials.gov (NCT03142191).</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-15DOI: 10.1164/rccm.202407-1295ED
Faping Wang, Min Zhu, Fengming Luo
{"title":"INTEGRIS-IPF: A New Hope for Tomorrow.","authors":"Faping Wang, Min Zhu, Fengming Luo","doi":"10.1164/rccm.202407-1295ED","DOIUrl":"10.1164/rccm.202407-1295ED","url":null,"abstract":"","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}